Xencor (NASDAQ:XNCR) Stock Rating Reaffirmed as Overweight by Cantor Fitzgerald

Key Points

• Cantor Fitzgerald reaffirmed its Overweight rating on Xencor and set a $70 price target, implying 99.83% upside from the previous close.
• Analyst sentiment overall is “Moderate Buy,” with an average price target of $42.22; published targets range from $21 to $70.
• Xencor reported quarterly EPS of $0.50, beating the $0.33-per-share loss analysts expected, while revenue of $116.52 million topped estimates of $63 million and rose 453.3% year over year.

Xencor (NASDAQ:XNCR - Get Free Report)'s stock had its "overweight" rating restated by equities research analysts at Cantor Fitzgerald in a research note issued on Thursday, Benzinga reports. They presently have a $70.00 price target on the biopharmaceutical company's stock. Cantor Fitzgerald's target price would suggest a potential upside of 99.83% from the company's previous close.

Several other research firms also recently weighed in on XNCR. Bank of America lifted their price objective on Xencor from $20.00 to $26.00 and gave the stock a "neutral" rating in a report on Monday, September 21st. Wells Fargo & Company upped their target price on Xencor from $30.00 to $44.00 and gave the company an "overweight" rating in a report on Tuesday, October 27th. JPMorgan Chase & Co. raised their price target on Xencor from $14.00 to $21.00 and gave the company a "neutral" rating in a research report on Thursday, September 3rd. Royal Bank Of Canada lifted their price target on Xencor from $20.00 to $43.00 and gave the stock an "outperform" rating in a research note on Tuesday, October 27th. Finally, Weiss Ratings reiterated a "sell (d-)" rating on shares of Xencor in a research report on Monday, September 21st. One investment analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average price target of $42.22.

Xencor Trading Up 14.3%

Shares of XNCR opened at $35.03 on Thursday. Xencor has a twelve month low of $10.38 and a twelve month high of $35.05. The firm has a market capitalization of $2.60 billion, a P/E ratio of -16.14 and a beta of 0.78. The firm's 50-day moving average is $25.92 and its two-hundred day moving average is $17.24.

Xencor (NASDAQ:XNCR - Get Free Report) last posted its quarterly earnings results on Wednesday, November 4th. The biopharmaceutical company reported $0.50 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.33) by $0.83. The company had revenue of $116.52 million during the quarter, compared to the consensus estimate of $63.00 million. Xencor had a negative net margin of 155.59% and a negative return on equity of 28.66%. The company's revenue for the quarter was up 453.3% on a year-over-year basis. During the same period last year, the firm earned ($0.08) EPS. Analysts predict that Xencor will post -3.05 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of XNCR. BlackRock Inc. acquired a new stake in shares of Xencor during the second quarter worth $219,785,000. Primecap Management Co. CA purchased a new stake in shares of Xencor during the 2nd quarter valued at $163,919,000. Dimensional Fund Advisors LP increased its holdings in shares of Xencor by 3.6% during the 1st quarter. Dimensional Fund Advisors LP now owns 1,294,887 shares of the biopharmaceutical company's stock worth $15,613,000 after buying an additional 45,599 shares during the last quarter. Legal & General Group Plc purchased a new position in shares of Xencor in the 2nd quarter worth $17,568,000. Finally, Johnson & Johnson acquired a new position in Xencor in the second quarter valued at $12,043,798.

Xencor Company Profile

Xencor, Inc is a clinical-stage biopharmaceutical company headquartered in Monrovia, California. Founded in 1997, the company develops engineered antibodies and other biologic medicines for the treatment of cancer, autoimmune disorders and other serious diseases.

Xencor's research is centered on its XmAb technology platform, which is designed to modify antibodies to improve their therapeutic properties or create new antibody-based mechanisms. The platform supports the development of bispecific antibodies, immune-cell engagers and antibodies with extended activity in the body.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.